Nuvation Bio Inc.

Nuvation Bio Inc.

NUVBNYSE / NASDAQHealthcareSmall cap

$3.80-$0.01 (-0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-8.8x
EV / EBITDA
-9.0x
Revenue
$62.9M
Net margin
-325.3%
ROCE
-41.6%

-45.8% over the last year

Nuvation Bio Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-20.3%
3M
-44.4%
6M
-15.7%
1Y
-45.8%
5Y
-58.0%

52-week range

Day change -$0.01 (-0.3%) from $3.81 to $3.80 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in NUVB, bought on each weekday since 2021.

News & filings

What Nuvation Bio filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 205 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue more than doubled in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Sector
Healthcare
Shares outstanding
346.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-8.8x
P/B
5.9x
EV / EBITDA
-9.0x
EV / Sales
26.9x
P/S
28.6x
52-week high
$9.54
52-week low
$3.78

Profitability

Operating margin
-338.7%
Net margin
-325.3%
EBITDA margin
-300.8%
ROE
-66.9%
ROCE
-41.6%
ROIC
-75.8%
ROA
-34.4%
Asset turnover
0.11

Growth

Revenue
$62.9M
Revenue growth, 1Y
699.0%
Net profit growth, 1Y
-64.0%
Free cash flow
-$181.8M

Solvency

Current ratio
6.95
Debt / Equity
0.19
Debt / Assets
0.10
CFO / Net profit
0.85
Cash / Market cap
9.1%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$62.9M
Cost of revenue$9.3M
Gross profit$53.6M
Operating expenses$266.7M
Research and development$115.1M
Selling, general and administrative$151.6M
Operating income-$213.1M
Interest and other$8.4M
Pretax income-$204.6M
Tax and other$0.00
Net income-$204.6M

Revenue and net profit

Revenue grew 699.0% in FY2025; net profit is the dashed line.

Nuvation Bio Inc. revenue and net profit by fiscal year
Nuvation Bio Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$104.2M
FY2023$0.00-$75.8M
FY2024$7.9M-$567.9M
FY2025$62.9M-$204.6M

Cash flows

FY2025: -$173.4M from operations, -$181.8M free after investment (dashed).

Nuvation Bio Inc. operating and free cash flow by fiscal year
Nuvation Bio Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$96.1M-$96.5M
FY2023-$68.0M-$68.1M
FY2024-$130.4M-$130.6M
FY2025-$173.4M-$181.8M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$62.9M+699.0%1Y
EBITDA
-$189.2M
Net profit
-$204.6M
Cash from operations
-$173.4M
Free cash flow
-$181.8M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$62.9M-$189.2M-$204.6M-$181.8M-66.9%+699.0%-64.0%

Monthly returns

Month-by-month returns of NUVB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$594.8M
Liabilities$289.1M
Equity$305.7M
Retained earnings-$1.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; NUVB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Nuvation Bio Inc. (this company)26.9x

Not shown (no positive earnings and no EV / Sales): Rapport Therapeutics, Inc., SELLAS Life Sciences Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Nuvation Bio Inc.NUVBthis company$1.8B-8.8x5.9x-66.9%-9.0x
Maravai LifeSciences Holdings, Inc.MRVI$1.8B-14.1x8.7x-61.6%-13.5x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Surgery Partners, Inc.SGRY$1.8B-23.0x1.0x-4.5%9.9x
SELLAS Life Sciences Group, Inc.SLS$1.8B-66.2x25.1x-37.9%-60.4x
Peer median—-5.3x3.2x-13.8%7.6x

Year-to-date ROI

NUVB since 1 January, against earlier years.

Historical volatility

NUVB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Nuvation Bio Inc. operating margin by fiscal year
Nuvation Bio Inc. operating margin by fiscal year
DateOperating margin
FY2024-2129.1%
FY2025-338.7%
LineFY2025
Cost of revenueCost Of Revenue$9.3M
Gross profitGross Profit$53.6M
Operating expensesOperating Expense$266.7M
Research and developmentResearch And Development$115.1M
Total expensesTotal Expenses$276.0M
Pretax incomePretax Income-$204.6M

Learn while you research

Academy chapters picked for Nuvation Bio Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing699% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →